Prognostic significance of TGFβ-1 and pSmad2/3 in breast cancer patients with T1-2N0 tumours

Anticancer Research

Volumn 27, Issue 4 C, 2007, Pages 2613-2620

  Koumoundourou, Dimitra ^a   Kassimatis, Theodoros ^a   Zolota, Vasiliki ^a   Tzorakoeleftherakis, Evangelos ^a   Ravazoula, Panagiota ^a   Vassiliou, Vassilios ^a   Kardamakis, Dimitrios ^a,b   Varakis, John ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b NONE   (Greece)

Author keywords

Breast cancer; Immunohistochemistry; pSmad2 3; Smad4; TGF 1

Indexed keywords

ESTROGEN RECEPTOR; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; PROGESTERONE RECEPTOR; SMAD2 PROTEIN, HUMAN; SMAD3 PROTEIN, HUMAN; SMAD4 PROTEIN; SMAD4 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; BIOSYNTHESIS; BREAST TUMOR; CANCER STAGING; FEMALE; METABOLISM; MIDDLE AGED; SIGNAL TRANSDUCTION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; RECEPTOR CROSS-TALK; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKERS, BIOLOGICAL;

EID: 34547778078     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Massague J: TGFβ signal transduction. Annu Rev Biochem 67: 753-791, 1998.
2. Wakefield LM, Piek E and Bottinger EP: TGF-beta signaling in mammary gland development and tumourigenesis. J Mammary Gland Biol Neoplasia 6: 67-82, 2001.
3. Hosobuchi M and Stampfer MR: Effects of transforming growth factor β on growth of human mammary epithelial cells in culture. In Vitro Cell Dev Biol 25: 705-713, 1989.
4. Pierce DF Jr, Johnson MD, Matsui Y, Robinson SD, Gold LI, Purchio AF, Daniel CW, Hogan BL and Moses HL: Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF 1. Genes Dev 7: 2308-2317, 1993.
5. Pierce DF Jr, Gorska AE, Chytil A, Meise KS, Page DL, Coffey RJ Jr and Moses HL: Mammary tumour suppression by transforming growth factor β 1 transgene expression. Proc Natl Acad Sci USA 92: 4254-4258, 1995.
6. Böttinger EP, Jakubczak JL, Haines DC et al: Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor β receptor show enhanced tumourigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[α]-anthracene. Cancer Res 57: 5564-5570, 1997.
7. Reiss M and Barcellos-Hoff MH: The role of transforming growth factor-β in breast cancer - a working hypothesis. Breast Cancer Res Treat 45: 81-95, 1995.
8. Wakefield LM, Yang YA and Dukhanina O: Transforming growth factor-p and breast cancer: lessons learnt from genetically altered mouse models. Breast Cancer Res 2: 100-106, 2000.
9. Walker RA and Dearing SJ: Transforming growth factor beta1 in ductal carcinoma in situ and invasive carcinomas of the breast. Eur J Cancer 28: 641-644, 1992.
10. Robinson SD, Silberstein GB, Roberts AB, Flanders KC and Daniel CW: Regulated expression and growth inhibitory effects of transforming growth factor-β isoforms in mouse mammary gland development. Development 113: 867-878, 1991.
11. Massague J, Blain SW and Lo RS: TGFb signalling in growth control, cancer, and heritable disorders. Cell 103: 295-309, 2000.
12. Yamamoto T, Saatcioglu F and Matsuda T: Cross-talk between bone morphogenic proteins and estrogen receptor signaling. Endocrinology 143: 2635-2642, 2002.
13. Brattain MG, Ko Y, Banerji SS, Wu G and Willson JK: Defects of TGF-beta receptor signaling in mammary cell tumourigenesis. J Mammary Gland Biol Neoplasia 1: 365-372, 1996.
14. Pouliot F and Labrie C: Expression profile of agonistic Smads in human breast cancer cells: absence of regulation by estrogens. Int J Cancer 81: 98-103, 1999.
15. Perry RR, Kang Y and Greaves BR: Relationship between tamoxifen-induced transforming growth factor beta 1 expression, cytostasis and apoptosis in human breast cancer cells. Br J Cancer 72: 1441-1446, 1995.
16. Wu L, Wu Y, Gathings B, Wan M, Grizzle W, Liu Z, Lu C, Mao Z and Cao X: Smad4 as a transcription corepressor for estrogen receptor. J Biol Chem 278: 15192-15200, 2003.
17. Kretzschmar M: Transforming growth factor-β and breast cancer - transforming growth factor-beta / SMAD signaling defects and cancer. Breast cancer Res 2: 107-115, 2002.
18. Schutte M, Hruban RH, Hedrick L, Cho KR, Nadasdy GM, Weinstein CL, Bova GS, Isaacs WB, Cairns P, Nawroz H, Sidransky D, Casero RA Jr, Meltzer PS, Hahn SA and Kern SE: DPC4 gene in various tumour types. Cancer Res 56: 2527-2530, 1996.
19. Chen T, Carter D, Garrigue-Antar L and Reiss M: Transforming growth factor-beta type I receptor kinase mutant associated with metastatic breast cancer. Cancer Res 58: 4805-4810, 1998.
20. Javelaud D and Mauviel A: Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-beta: implications for carcinogenesis. Oncogene 24: 5742-5750, 2005.
21. Elliott RL and Blobe GC: Role of transforming growth factor Beta in human cancer. J Clin Oncol 23: 2078-2093, 2005.
22. Imamichi Y, Waidmann O, Hein R,Eleftheriou P, Giehl K and Menke A: TGF beta-induced focal complex formation in epithelial cells is mediated by activated ERK and JNK MAP kinases and is independent of Smad4. Biol Chem 386: 225-236, 2005.
23. Kamaraju AK and Roberts AB: Role of Rho/ROCK and p38 MAP kinase pathways in transforming growth factor-beta-mediated Smad-dependent growth inhibition of human breast carcinoma cells in vivo. J Biol Chem 280: 1024-1036, 2005.
24. Tian F, Byfield SD, Parks WT, Stuelten CH, Nemani D, Zhang YE and Roberts AB: Smad-binding defective mutant of transforming growth factor beta type I receptor enhances tumourigenesis but suppresses metastasis of breast cancer cell lines. Cancer Res 64: 4523-4530, 2004.
25. Kim SJ, Im YH, Markowitz SD and Bang YJ: Molecular mechanisms of inactivation of TGF-beta receptors during carcinogenesis. Cytokine Growth Factor Rev 11: 159-168, 2000.
26. Ammanamanchi S and Brattain MG: Sp3 is a transcriptional repressor of transforming growth factor-beta receptors. J Biol Chem 276: 32854-32859, 2001.
27. Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynch R and Dickson RB: Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48: 417-428, 1987.
28. Chen H, Tritton TR Kenny N, Absner M and Chiu JF: Tamoxifen induces TGFβ-1 activity and apoptosis of human MCF-7 breast cancer cells in vitro. J Cell Biochem 61: 9-17, 1996.
29. Koli KM, Ramsey TT, Ko Y, Dugger TC, Brattain MG and Arteaga CL: Blockade of transforming growth factor-beta signaling does not abrogate antiestrogen- induced growth inhibition of human breast carcinoma cells. J Biol Chem 272: 8296-8302, 1997.
30. Malet C, Fibleuil F, Mestayer C, Mowszowicz I and Kuttenn F: Estrogen and antiestrogen actions on transforming growth factor-β (TGF) in normal human breast epithelial (HBE) cells Mol Cell Endocrinol 174: 21-30, 2001.
31. Ewan KB, Oketch-Rabah HA, Ravani SA, Shyamala G, Moses HL and Barcellos-Hoff MH: Proliferation of estrogen receptor-alpha-positive mammary epithelial cells is restrained by transforming growth factor-beta1 in adult mice. Am J Pathol 167: 409-417, 2005.
32. Buck MB, Pfizenmaier K and Knabbe C: Antiestrogens induce growth inhibition by sequential activation of p38 mitogen-activated protein kinase and transforming growth factor-beta pathways in human breast cancer cells. Mol Endocrinol 18: 1643-1657, 2004.
33. Rosen PP, Groshen S, Kinne DW and Norton L: Factors influencing prognosis in node-negative breast carcinoma: Analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol 11: 2090-2100, 1993.
34. Karayiannakis AJ, Bastounis EA, Chatzigianni EB, Makri GG, Alexiou D and Karamanakos P: Immunohistochemical detection of oestrogen receptors in ductal carcinoma in situ of the breast. Eur J Surg Oncol 22: 578-582, 1996.
35. Becker KA, Lu S, Dickinson ES, Dunphy KA, Mathews L, Schneider SS and Jerry DJ: Estrogen and progesterone regulate radiation-induced p53 activity in mammary epithelium through TGF-beta-dependent pathways. Oncogene 24: 6345-6353, 2005.
36. Xie W, Mertens JC, Reiss DJ, Rimm DL, Camp RL, Haffty BG and Reiss M: Alterations of Smad Signaling in Human Breast Carcinoma Are Associated with Poor Outcome: A Tissue Microarray Study. Cancer Research 62: 497-505, 2002.